FY2025 EPS Estimates for Biogen Lowered by Leerink Partnrs

Biogen Inc. (NASDAQ:BIIB) – Analysts at Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for Biogen in a report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the biotechnology company will post earnings of $16.50 per share for the year, down from their previous forecast of $17.20. The consensus estimate for Biogen’s current full-year earnings is $16.41 per share. Leerink Partnrs also issued estimates for Biogen’s FY2026 earnings at $16.65 EPS.

BIIB has been the subject of several other reports. Oppenheimer reduced their price objective on Biogen from $270.00 to $255.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. William Blair restated an “outperform” rating on shares of Biogen in a research report on Monday, January 13th. BMO Capital Markets downgraded Biogen from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $230.00 to $164.00 in a research report on Friday, December 20th. Truist Financial cut their price objective on Biogen from $302.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Finally, TD Cowen cut their price objective on Biogen from $300.00 to $275.00 and set a “buy” rating for the company in a research report on Thursday, October 31st. Sixteen analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $228.80.

Biogen Stock Performance

Shares of NASDAQ BIIB opened at $146.23 on Thursday. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28. The stock has a 50 day simple moving average of $151.32 and a 200-day simple moving average of $179.80. The company has a market cap of $21.31 billion, a PE ratio of 13.21, a P/E/G ratio of 1.64 and a beta of -0.07. Biogen has a 12-month low of $139.71 and a 12-month high of $251.99.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $4.08 EPS for the quarter, beating the consensus estimate of $3.77 by $0.31. The company had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.43 billion. Biogen had a return on equity of 14.98% and a net margin of 16.81%. The business’s revenue was down 2.5% compared to the same quarter last year. During the same period in the prior year, the company earned $4.36 earnings per share.

Hedge Funds Weigh In On Biogen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Ashton Thomas Securities LLC bought a new position in shares of Biogen during the third quarter worth $33,000. Venturi Wealth Management LLC lifted its position in Biogen by 73.8% in the 3rd quarter. Venturi Wealth Management LLC now owns 219 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 93 shares in the last quarter. Itau Unibanco Holding S.A. lifted its position in Biogen by 63.8% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 231 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 90 shares in the last quarter. Golden State Wealth Management LLC bought a new stake in Biogen in the 4th quarter valued at $41,000. Finally, Quent Capital LLC lifted its position in Biogen by 31.9% in the 4th quarter. Quent Capital LLC now owns 298 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 72 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.